Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: Tumor mutation burden and PD-L1 ≥50%

dc.creator	Zarogoulidis P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y.-G., Bai C., Huang H.	en
dc.date.accessioned	2023-01-31T11:38:21Z
dc.date.available	2023-01-31T11:38:21Z
dc.date.issued	2018
dc.identifier	10.21037/tlcr.2018.01.04
dc.identifier.issn	22186751
dc.identifier.uri	http://hdl.handle.net/11615/80964
dc.description.abstract	[No abstract available]	en
dc.language.iso	en	en
dc.source	Translational Lung Cancer Research	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041825444&doi=10.21037%2ftlcr.2018.01.04&partnerID=40&md5=1840bf7d499c0cea5bcee1e362d64363
dc.subject	nivolumab	en
dc.subject	pembrolizumab	en
dc.subject	programmed death 1 ligand 1	en
dc.subject	cancer chemotherapy	en
dc.subject	cancer immunotherapy	en
dc.subject	drug safety	en
dc.subject	Editorial	en
dc.subject	gene mutation	en
dc.subject	human	en
dc.subject	liver metastasis	en
dc.subject	non small cell lung cancer	en
dc.subject	overall survival	en
dc.subject	protein expression	en
dc.subject	tumor biopsy	en
dc.subject	AME Publishing Company	en
dc.title	Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: Tumor mutation burden and PD-L1 ≥50%	en
dc.type	other	en

Αρχεία σε αυτό το τεκμήριο

Αρχεία	Μέγεθος	Τύπος	Προβολή
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.